Sunshine Biopharma hires Aegis Capital as warrant solicitation agent for 3 months, 10% fee on proceeds

Sunshine Biopharma Inc.

Engaged Aegis Capital on March 6, 2026 to induce exercise of outstanding warrants on best-efforts basis.
Term of engagement agreement is three months; Aegis receives 10% of gross proceeds from warrant exercises.
Company agreed to reimburse Aegis up to $100,000 for legal fees and expenses.
Engagement includes exclusivity provision: Company cannot solicit other financing during term except existing debt holders.
Warrants trade under ticker SBFMW on Nasdaq; proceeds would provide non-dilutive capital to the company.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.